

Ref: FOIA Reference 2024/25-493

Royal Stoke University Hospital  
Data, Security and Protection  
Newcastle Road  
Stoke-on-Trent  
Staffordshire  
ST4 6QG

Date: 20<sup>th</sup> November 2024

Email [foi@uhnm.nhs.uk](mailto:foi@uhnm.nhs.uk)

Dear Sir/ Madam

I am writing to acknowledge receipt of your email dated 23rd October 2024 requesting information under the Freedom of Information Act (2000) regarding chronic lymphocytic leukaemia (CLL)

**Q1** How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

A1 Twenty (20)

**Q2** How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

A2 Nil

**Q3** Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

- FCR (fludarabine + cyclophosphamide + rituximab)
- FR (fludarabine + rituximab)
- BR (bendamustine + rituximab)
- Bendamustine monotherapy
- RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
- Obinutuzumab ± chlorambucil
- Rituximab + chlorambucil
- Ofatumumab
- Other – please specify

**Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window**

**Answer:**

| Treatment option            | Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024 |
|-----------------------------|--|
| FCR                         |  |
| FR                          |  |
| BR                          |  |
| Bendamustine monotherapy    |  |
| R-CHOP                      |  |
| Obinutuzumab ± chlorambucil |  |
| Rituximab + chlorambucil    |  |
| Chlorambucil monotherapy    |  |
| Rituximab monotherapy       |  |
| Ofatumumab                  |  |
| Other – please specify      |  |

A3 See below:

| Treatment option            | Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024 |
|-----------------------------|--|
| FCR                         | 0  |
| FR                          | 0  |
| BR                          | 0  |
| Bendamustine monotherapy    | 0  |
| R-CHOP                      | 0  |
| Obinutuzumab ± chlorambucil | 0  |
| Rituximab + chlorambucil    | 0  |
| Chlorambucil monotherapy    | 0  |
| Rituximab monotherapy       | 0  |
| Ofatumumab                  | 0  |

|                        |  |
|------------------------|--|
| Treatment option       | Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024 |
| Other – please specify | 0  |

\*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

***UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.***

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust’s disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust’s FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner’s Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via [www.ico.org.uk](http://www.ico.org.uk).

Yours,



University Hospitals  
of North Midlands  
NHS Trust

*L Carlisle*

**Leah Carlisle**

Head of Data, Security & Protection and Health Records  
Data Protection Officer

